XNAS
KZIA
Market cap14mUSD
Oct 08, Last price
8.82USD
1D
-5.06%
1Q
-34.96%
Name
Kazia Therapeutics Ltd
Chart & performance
P/E
—
P/S
486.80
EPS
—
Div yield, %
—
Shrs. gr., 5y
48.35%
Rev. gr., 5y
-46.83%
Revenues
42k
-98.18%
Net income
-21m
L-22.69%
CFO
-13m
L+38.59%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Kazia Therapeutics Limited is a biotechnology firm specializing in oncology, committed to developing innovative therapies for cancer. Its flagship product candidate, Paxalisib, is a brain-penetrant small molecule that inhibits the PI3K/Akt/mTor pathway and is currently being investigated as a potential treatment for glioblastoma. Additionally, the company is progressing EVT801, an investigational new drug aimed at combating various types of cancer. Established in 1994 and headquartered in Sydney, Australia, the entity was formerly known as Novogen Limited before adopting the name Kazia Therapeutics Limited in November 2017.
Key people
Karen Krumeich
Chief Financial Officer · since 2022
John Friend
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director · since 2023
Lilischkis Kimberley
Clinical & Regulatory Affairs Manager
Peng Leong
Chief Business Officer · since 2016
Stephen Palmer
Program Director - Degenerative Diseases · since 2014
Justine Stehn
Director - ATM Program · since 2014
Anna Sandham
Company Secretary · since 2023
Steven Coffey
Non-Executive Director · since 2012
Bryce Carmine
Non-Executive Independent Director · since 2019
Ebru Davidson
Non-Executive Independent Director · since 2023
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||